PMM-PMI, Leukocytes
GTR Test Accession: Help GTR000603795.2
INHERITED DISEASEMETABOLIC DISEASEIMMUNOLOGY ... View more
Last updated in GTR: 2024-04-25
Last annual review date for the lab: 2024-05-28 LinkOut
At a Glance
Diagnosis
PMM2-congenital disorder of glycosylation; MPI-congenital disorder of glycosylation
phosphomannomutase; phosphomannose isomerase
Biochemical Genetics - Enzyme assay: Enzyme activity
Diagnosing congenital disorders of glycosylation Ia (phosphomannomutase-2 deficiency: CDG-Ia or …
Not provided
Establish or confirm diagnosis
Ordering Information
Offered by: Help
Test short name: Help
PMMIL
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Dentist
  • Licensed Physician
  • Nurse Practitioner
  • Physician Assistant
  • Public Health Mandate
  • Registered Nurse
Lab contact: Help
Gisele (Gessi) Bentz Pino, MS, CGC, Certified Genetic counselor, CGC, Genetic Counselor
biochemicalgenetics@mayo.edu
1-800-533-1710
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
https://www.mayocliniclabs.com/test-catalog/overview/89656#Specimen
Order URL
Test development: Help
Test developed by laboratory but exempt from FDA oversight (eg. NYS CLEP approved, offered within a hospital or clinic)
Informed consent required: Help
Based on applicable state law
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 2
Condition/Phenotype Identifier
Test Targets
Analytes Help
Total analytes: 2
Analyte Associated Condition
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument *
Enzyme assay
Enzyme activity
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis
Target population: Help
Diagnosing congenital disorders of glycosylation Ia (phosphomannomutase-2 deficiency: CDG-Ia or PMM2-CDG) and Ib (phosphomannose isomerase deficiency: CDG-Ib or MPI-CDG). Follow-up testing for patients with an abnormal transferrin isoform profile. This test is not useful for carrier testing.
View citations (3)
  • Grünewald S, Schollen E, Van Schaftingen E, Jaeken J, Matthijs G. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet. 2001;68(2):347-54. doi:10.1086/318199. Epub 2001 Jan 11. PMID: 11156536.
  • Girard M, Douillard C, Debray D, Lacaille F, Schiff M, Vuillaumier-Barrot S, Dupré T, Fabre M, Damaj L, Kuster A, Torre S, Mention K, McLin V, Dobbelaere D, Borgel D, Bauchard E, Seta N, Bruneel A, De Lonlay P. Long term outcome of MPI-CDG patients on D-mannose therapy. J Inherit Metab Dis. 2020;43(6):1360-1369. doi:10.1002/jimd.12289. Epub 2020 Aug 09. PMID: 33098580.
  • Jaeken J, Matthijs G, Carchon H, Van Schaftingen E: Defects of N-glycan synthesis. In: Valle D, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed July 20, 2021. Available at https://ommbid.mhmedical.com/content.aspx?sectionid=225081470
Recommended fields not provided:
Technical Information
Test Procedure: Help
Leukocytes are harvested from one 7-mL tube of ACD-treated blood and the resulting leukocyte cell pellet is subjected to 1 freeze-thaw cycle. The lysate is collected and the enzymatic activity for both phosphomannomutase and phosphomannose isomerase is measured by a colorimetric assay.(Personal communication: Dr. Otto van Diggelen, Erasmus University, Rotterdam, … View more
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
Accuracy was assessed by analysis of positive and negative samples; 100% clinical concordance was achieved.Intra assay precision was performed at 3 levels: CV results ranged from 3.9%-18.8% (N=20 each). Inter assay precision was performed at 3 levels: CV results ranged from 6.1%-25.1% (N=20 each). The analytical measurement range is enzyme … View more
Assay limitations: Help
There are some known carriers of phosphomannomutase-2 deficiency (PMM2) who have reduced enzyme activity that falls in the range of affected patients with PMM2-congenital disorders of glycosylation (CDG). The PMM2 enzyme result should be considered along with CDG transferrin, clinical phenotype, and genotype when determining a diagnosis.
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Intra-Laboratory

Description of PT method: Help
Intra-laboratory alternative assessment of performance through quality control or patient blind testing

Description of internal test validation method: Help
This test was laboratory developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements.
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Category: FDA exercises enforcement discretion
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.